{"doi":"10.3109/10428194.2010.543717","title":"Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)","abstract":null,"journal":"Leukemia & Lymphoma","year":2011,"id":610537,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1569754,"name":"Carlos Montalbán","orcid":null,"position":1,"is_corresponding":false},{"id":1569755,"name":"Alberto Fernández De Sevilla","orcid":null,"position":2,"is_corresponding":false},{"id":1569756,"name":"JoaquÍn MartÍnez-lópez","orcid":null,"position":3,"is_corresponding":false},{"id":1569757,"name":"Nicolás DÍaz","orcid":null,"position":4,"is_corresponding":false},{"id":1569758,"name":"Miguel Canales","orcid":null,"position":5,"is_corresponding":false},{"id":1569759,"name":"Rafael MartÍnez","orcid":null,"position":6,"is_corresponding":false},{"id":1569760,"name":"Pedro Sánchez-Godoy","orcid":null,"position":7,"is_corresponding":false},{"id":1569761,"name":"MarÍa Dolores Caballero","orcid":null,"position":8,"is_corresponding":false},{"id":1569762,"name":"Javier Peñalver","orcid":null,"position":9,"is_corresponding":false},{"id":1569763,"name":"Elena Prieto","orcid":null,"position":10,"is_corresponding":false},{"id":1569764,"name":"Antonio Salar","orcid":null,"position":11,"is_corresponding":false},{"id":1569765,"name":"Carmen Burgaleta","orcid":null,"position":12,"is_corresponding":false},{"id":1569766,"name":"José Antonio Queizán","orcid":null,"position":13,"is_corresponding":false},{"id":1569767,"name":"Roberto Bajo","orcid":null,"position":14,"is_corresponding":false},{"id":1569768,"name":"Raquel De oña","orcid":null,"position":15,"is_corresponding":false},{"id":1569769,"name":"Javier De La Serna","orcid":null,"position":16,"is_corresponding":false},{"id":1569753,"name":"José Francisco Tomás","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).","abstract":"We assessed the efficacy of fludarabine, cyclophosphamide, and rituximab in combination (FCR) as frontline treatment in patients with follicular lymphoma (FL) followed by rituximab maintenance. Seventy-five untreated patients with FL received FCR followed by maintenance with rituximab 375 mg/m(2) weekly during 4 weeks and every 6 months for 2 years. The overall response rate was 100%, with 89% complete remission (CR) and 11% partial remission (PR). Molecular remission was observed in all but one patient. Only eight patients completed all therapy planned. With a median follow-up of 47 months, the 5-year overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) were 77%, 93%, and 72%, respectively. Age below 60 and low Follicular Lymphoma International Prognostic Index (FLIPI) correlated with a better EFS. Ten patients died due to toxic complications. The FCR regimen is highly effective in untreated patients with FL, with 89% CR, including molecular responses, and a low progression rate. However, the high incidence of treatment-related mortality makes this regimen unsafe and it cannot be recommended as an upfront therapy in FL.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21275633","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"green","license":"other-oa","oa_locations":[{"url":"http://hdl.handle.net/20.500.11940/6905","host_type":"repository"}],"fields_of_study":[],"mesh_terms":["Humans","Lymphoma, Follicular","Cyclophosphamide","Vidarabine","Antineoplastic Combined Chemotherapy Protocols","Antibodies, Monoclonal","Treatment Outcome","Chemotherapy, Adjuvant","Neoadjuvant Therapy","Drug Administration Schedule","Cooperative Behavior","Adult","Aged","Middle Aged","Spain","Female","Male","Clinical Trials as Topic","Young Adult","Antibodies, Monoclonal, Murine-Derived","Drug-Related Side Effects and Adverse Reactions","Rituximab"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T23:07:57.466377Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}